New Adjuvant Drug for Lung Cancer

Am J Nurs. 2021 Apr 1;121(4):23-24. doi: 10.1097/01.NAJ.0000742492.40886.52.

Abstract

A new adjuvant treatment, osimertinib (Tagrisso), has been approved for patients with non-small cell lung cancer whose tumors have certain mutations.The most common adverse effects of treatment are leukopenia, lymphopenia, thrombocytopenia, diarrhea, anemia, rash, musculoskeletal pain, nail toxicity, neutropenia, dry skin, stomatitis, fatigue, and cough.

MeSH terms

  • Acrylamides / therapeutic use*
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / surgery*
  • Chemotherapy, Adjuvant
  • Drug-Related Side Effects and Adverse Reactions
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / surgery*
  • Male
  • Middle Aged
  • Protein Kinase Inhibitors / therapeutic use*

Substances

  • Acrylamides
  • Antineoplastic Agents
  • Protein Kinase Inhibitors